IJCRR - 10(7), April, 2018
Pages: 06-11
Rationale for Palliative Gastrectomy and Metastasectomy in Metastatic Gastric Cancer
Author: Abdullah Sakin, Makbule Tambas, Nurgul Yasar, Caglayan Geredeli, Saban Secmeler, Cumhur Demir, Ali Alemdar, Hakan Guven, Sener Cihan
Category: Healthcare
[Download PDF]
Abstract:
Objectives: Approximately 50% of gastric cancer patients are locally advanced or metastatic staged at the time of diagnosis. In limited metastatic patients, performing surgery is thought to be related to survival benefit. Thus, we evaluated the effect of the surgery on survival in patients with metastatic gastric carcinoma who have been treated and followed-up in our oncology clinic.
Methods: Patients with pathologically verified metastatic gastric cancer between 2009-2016 were included in the study.The patients were divided into 3 groups as those who underwent palliative gastrectomy (group A), who underwent simultaneous gastric surgery and metastasectomy (group B), and who underwent no surgery (group C).
Results: One hundred and fifty-three patients, including 35 in the group A, 10 in the group B, and 108 in the group C, were included in the study. There was a significant difference between the groups in terms of the mean age of the patients (60,4, 53 and 63, respectively; p=0.016). Median follow-up time was 8±9.6 months. Medianoverall survival (OS) was 20 months in group
B, 13 months in group A and 6 months in group C;while OS was found to be significantly increased in surgery groups compared with non-surgery (Group A vs. B, p=0,259; group A vs. C, p<0,001; group B vs. C, p<0,001).
Conclusions: It is determined that performing surgery for primary tumor and/or its oligomatastases provided survival benefit
in patients with good performance in metastatic gastric cancer. Further prospective studies with higher number of patients are
warranted in this subject.
Keywords: Chemotherapy, Gastrectomy, Gastric cancer, Metastasectomy
DOI: 10.7324/IJCRR.2018.1072
Citation:
Abdullah Sakin, Makbule Tambas, Nurgul Yasar, Caglayan Geredeli, Saban Secmeler, Cumhur Demir, Ali Alemdar, Hakan Guven, Sener Cihan. Rationale for Palliative Gastrectomy and Metastasectomy in Metastatic Gastric Cancer International Journal of Current Research and Review. 10(7), April, 06-11
References:
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
2. Jeong O, Park YK, Choi WY, Ryu SY. Prognostic significance of non-curative gastrectomy for incurable gastric carcinoma. Ann Surg Oncol. 2014;21(8):2587-93.
3. Chen J, Kong Y, Weng S, Dong C, Zhu L, Yang Z, et al. Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database. Oncotarget. 2017;8(3):4342-51.
4. Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17(2):206-12.
5. Martella L, Bertozzi S, Londero AP, Steffan A, De Paoli P, Bertola G. Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore). 2015;94(31):e1113.
6. Tegels JJ, De Maat MF, Hulsewe KW, Hoofwijk AG, Stoot JH. Improving the outcomes in gastric cancer surgery. World J Gastroenterol. 2014;20(38):13692-704.
7. Linhares E, Monteiro M, Kesley R, Santos CE, Filho OS, Simoes JH. Major hepatectomy for isolated metastases from gastric adenocarcinoma. HPB (Oxford). 2003;5(4):235-7.
8. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146-53.
9. Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010;4(1):406-13.
10. Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, Gotz M, Scheuerlein H, Jandt K, et al. Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature. Gastric Cancer. 2012;15(2):131-6.
11. Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, et al. Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience. World J Surg. 2016;40(4):921-8.
12. Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, et al. Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res. 2012;32(8):3397-401.
13. Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, et al. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget. 2017;8(47):82558-70.
14. Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017;16(1):19.
15. Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, et al. Survival benefit of gastrectomy +/- metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer. 2011;14(2):130-8.
|